David's coverage specializes in OTC medicines, dietary supplements and self-care medical devices. David is interested in regulatory gray areas such as the borderlines between medicines, supplements and medical devices, as well as botanical ingredients. David also regularly speaks to industry leaders and experts about the latest trends to deliver crucial market intelligence to HBW Insight readers, and co-hosts the Over the Counter podcast. In his spare time, David spends time in his allotment garden, reading/watching science fiction and worrying about climate change.
Latest from David Ridley
AI advisers could eventually guide consumers toward health products based on personalized needs rather than traditional marketing, IQVIA Consumer Health suggests. But brands will still need to balance data‑driven recommendations with the human appeal of in‑store discovery and self‑care experiences.
Germany’s Expert Committee for Prescription (SVA) has unanimously rejected the proposed switch of the controversial painkiller metamizole from prescription to OTC status.
Featuring: Prevention‑driven reforms in Vietnam; surging demand for OTC and herbal based interventions in China; Singapore updates its health data infrastructure; regional regulatory harmonization across Australia, Singapore and Indonesia; and WHO sets formal direction for TCIM.
Umbrella branding in OTC medicines supports responsible self‑care by helping consumers navigate choices, build trust and confidence, and access reliable health information, countering regulators’ long‑standing focus on risks rather than benefits, says PAGB CEO Michelle Riddalls.
A new Lancet meta-analysis finds no evidence that paracetamol use in pregnancy increases the risk of autism, ADHD, or intellectual disability, decisively refuting claims made by US President Donald Trump and reaffirming regulatory guidance that the drug remains safe when used as directed.
HBW Insight speaks to ex-Perrigo ESG expert Steve Ramus about the state of sustainability in consumer health and where we might be heading in the near future. Part one of two.